Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Cell & Gene Meeting 2024 in Rome
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Advanced Therapies 2024 in London
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to RNA Leaders Europe Congress 2024 in Basel, Switzerland.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to mRNA Based Therapeutics Summint 2024 in Berlin.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in Miami
read moreHow Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)
read moreAt the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities
read moreThe Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer
read moreA new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
